All In Biotech

Drug Trial Radar · NCT06090266

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

A Phase 1/2 Study of OR502 Alone and in Combination With Other Anti-cancer Agents in Subjects With Advanced Malignancies

Last checked: Nov 19, 2026Latest source record: Jan 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

168

Planned (sponsor's estimate)

Start

Oct 24, 2023

Primary completion

Aug 1, 2026

Study completion Feb 1, 2027

Sponsor

Lead sponsor
OncoResponse, Inc.Industry
Sponsor type
Industry
First posted
Oct 19, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR502 administered as a monotherapy and in combination with cemiplimab in subjects with advanced solid tumors.

Conditions

  • Cancer
  • Tumor, Solid
  • Malignant Neoplasm
  • Metastatic Cancer
  • Advanced Solid Tumor
  • Cutaneous Melanoma
  • Non-small Cell Lung Cancer

Interventions

  • OR502Drug

    IgG1 monoclonal antibody that binds specifically to the LILRB2 protein.

  • CemiplimabDrug

    IgG4 mAb that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting ToxicityTime frame: First 21 days of treatment.
  2. Adverse Events and Serious Adverse EventsTime frame: Screening to 90 days from last dose.
  3. Vital SignsTime frame: Screening to 90 days from last dose.
  4. Recommended Dose and Regimen (mono and combination therapy)Time frame: Screening to 90 days from last dose.

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • NEXT Austin

    Austin, Texas · Recruiting

  • NEXT Dallas

    Irving, Texas · Recruiting

  • NEXT Oncology

    San Antonio, Texas · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.